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Purpose: The aim of this study was to compare the outcome of consecutive patients with
abdominal aortic aneurysm (AAA) treated concurrently by open operation and endolumi-
nal intervention by the same surgeons during a defined interval.
Methods: Between May 1992 and May 1996, 362 consecutive patients with AAA underwent
repair. Fifty-three patients who underwent open operations for ruptured AAA plus two
patients who underwent endoluminal repair of false AAA and four patients who underwent
secondary endoluminal repair of AAA were excluded, leaving 303 patients who underwent
elective repair of true AAA in the study. The elective operations were conventional open
repair (OR) in 195 patients (151 men, 44 women; mean age, 69 years) and endoluminal
repair (ER) in 108 patients (100 men, 8 women; mean age, 70 years). The decision to per-
form ER was based on comorbidities that precluded open repair (n = 48) and patient choice
(n = 60). Graft configuration in the open repair group was tubular (n = 180) and bifurcat-
ed (n = 15), and in the ER group tubular (n = 48), aortoiliac/femoral (n = 25), and bifur-
cated (n = 35). All procedures were performed in the operating department, and radi-
ographic guidance was used in the ER group. Follow-up was by interview, examination, and
telephone. In addition, contrast-enhanced computed tomography was performed within the
first 10 days after operation, 6 months and 12 months after operation, and then annually
thereafter in the ER group. Outcome measures were successful exclusion of the aneurysm
sac from the general circulation and survival. Data were analyzed by the life table method.
Other outcome measures were length of hospital stay, length of intensive care unit stay, and
operative blood loss.
Results: No significant difference was found between the perioperative mortality rate for OR
(11 deaths [5.6%] in 195 patients) and ER (six deaths [5.6%] in 108 patients). Three of the
six deaths in the latter group occurred in patients with successful ER, and three occurred in
18 patients with failed ER who were converted to OR. Similarly, no significant difference
was seen in the survival rate between the endoluminal and open repair groups when ana-
lyzed by the log-rank test (p = 0.14). The rate of graft failure, however, was significantly
higher in the ER group than in the OR group (Fisher’s exact test, p < 0.001). Success in the
ER group was defined as continuing graft function without endoleak or conversion to open
repair. Kaplan-Meier curve for graft failure times for the endoluminal group revealed a 3-
year graft success probability of 70%.
Conclusions: This study suggests that ER is safe, sharing the same perioperative mortal-
ity risk as OR despite 44% of the ER group being rejected as unfit for OR. Conventional
open repair is the most reliable method of successfully managing AAA. The endolumi-
nal method, however, results in shorter length of hospital stay, shorter length of inten-
sive care unit stay, and less blood loss than the open method. Patients who opt for the
endoluminal method of repair should be made aware that the minimally invasive tech-
nique carries the disadvantage of a higher failure rate. (J Vasc Surg 1998;27:213-21.)
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The minimally invasive nature of the endolumi-
nal method of abdominal aortic aneurysm (AAA)
repair has always been attractive. The long-term out-
come, however, is unknown. Numerous reports to
date have established the feasibility and relative safe-
ty of various endoluminal devices and techniques in
the management of AAA.1-8 In a previous study we
compared the outcome of patients who underwent
endoluminal repair (ER) with a historic matched
control group of patients who underwent open
repair (OR) of AAA.9 To date, however, there have
been no reports of concurrent comparison of the two
methods. Many excellent reports of endoluminal
AAA repair have lacked sufficient numbers or dura-
tion of follow-up to give an indication of long-term
outcome.10,11 In an attempt to overcome these defi-
ciencies we present a concurrent comparison of ER
versus OR in consecutive patients with AAA with
analysis by the life table method over a 5-year period.
METHODS
Between May 1992 and May 1996, 362 consec-
utive patients with AAA underwent repair. Fifty-
three patients who underwent open operations for
ruptured AAA were excluded. In addition, two
patients who underwent ER of false AAA and four
patients who underwent secondary ER of AAA were
excluded. The secondary ER operations were per-
formed on patients who underwent a primary ER
and had an endoleak.12 The study group consisted
of 303 patients who underwent primary elective
repair of true AAA. The elective operations were
conventional OR in 195 patients and ER in 108
patients. The decision to perform ER was based on
comorbidities that precluded OR (n = 48) and
patient choice (n = 60). ER was restricted to those
patients whose aneurysms were morphologically
suitable for the method and was further limited by
lack of information on long-term outcome in the
early phase of the study.
ER group. Prospective data were recorded for
108 consecutive patients who underwent ER. One
hundred male patients and eight female patients
with a mean age of 70 years were evaluated. Comor-
bidities sufficiently severe to preclude OR at other
medical centers were present in 48 patients (Table
I). Two thirds of these referrals came from specialist
vascular surgeons, and all referrals were on the basis
of patient ill health rather than inadequate facilities
to undertake the procedure. Many patients had
medical conditions in addition to the comorbidities
that excluded them from OR. Four patients with
severe cardiac disease also had renal impairment
insufficiently severe, of itself, to preclude OR. These
medical conditions are listed in Patient Characteris-
tics and are summarized in Table II. Detailed imag-
ing by contrast-enhanced computed tomography
and aortography were performed before surgery in
all patients. Anatomic criteria for endoluminal graft-
ing based on these investigations included a proxi-
mal aneurysm neck of length 15 mm or greater, a
diameter of 28 mm or less, and no evidence of a
patent inferior mesenteric artery arising from the
aneurysms.
Technique of endoluminal aneurysm repair.
The program of endoluminal grafting was approved
by the Institutional Research Review Board and
Ethics Committee. Informed consent was obtained
from each patient. All procedures were performed in
the operating department with patients prepared
and draped for conventional open operation in the
event that conversion to OR was required in cases of
failed endoluminal technique or the occurrence of
serious complications.
The endografts used were a modification of the
Parodi device (n = 10), the EVT endograft (Endovas-
cular Technologies, Menlo Park, Calif.; n = 15), the
White-Yu endograft (n = 68), the Chuter device (n =
1), and the Stentor (Mintec; n = 14). The EVT endo-
grafts were all phase I devices. Three were found to
have hook fractures at 1-year follow-up, but these
have not resulted in any adverse event. The graft con-
figuration was tubular (n = 48), aortoiliac/femoral (n
= 25), and bifurcated (n = 35). The aortoiliac/femoral
configuration was combined with interruption of the
contralateral common iliac artery with either a
detachable balloon, a blind ended covered stent, or
surgical ligation. These maneuvers excluded the
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Table I. Cormorbidities
No.
Severe cardiac disease
ASA Stage 3b or 4 25
Renal failure
On dialysis 1
Successfully transplanted 1
Severe respiratory disease 8
Boushy Category III*
Chronic liver disease— 4
cirrhosis/portal hypertension
Childs’ Category A or B†
Hostile abdomen 9
Total 48
ASA, American Society of Anesthetists.
*Boushy: Classification of grade of dyspnoea modified and report-
ed in Anaesthetic implications of concurrent diseases.13
†Childs’ criteria for hepatic functional reserve.
aneurysm sac from retrograde collateral filling. A
femorofemoral crossover graft was required to per-
form revascularization on the contralateral lower
limb. Prophylactic antibiotics were administered at
the time of induction of anesthesia. All patients
underwent anticoagulation with 5000 U heparin
administered intravenously after the access artery
was exposed. Monitoring of the anticoagulation sta-
tus was not used. Access was restricted to the
femoral arteries in 90 patients, whereas the common
iliac arteries were used with an extraperitoneal
approach in 18 patients. The techniques for the
transfemoral and extraperitoneal iliac approaches
have been described in detail previously.1,2,6-11 Flu-
oroscopic monitoring was used in the delivery and
deployment of all endografts. On table completion
angiography was undertaken in all patients.
Follow-up. Contrast-enhanced computed tomog-
raphy was performed within the first 10 days after
operation, at 6 months and 12 months after opera-
tion, and then annually thereafter. Most of these
investigations were performed at the authors’ insti-
tution, and those that were not were done at the
authors’ direction and the resulting scans viewed by
them. Outcome measures for this study were sur-
vival and successful outcome after primary AAA
repair. Success in the ER group was defined as con-
tinuing graft function without endoleak or conver-
sion to OR. A decrease in maximum transverse
diameter of AAA after ER is also an important para-
meter in the assessment of success, and this was
monitored regularly. Persistent endoleak was classi-
fied as a failure irrespective of whether successful sec-
ondary ER repair was subsequently achieved. Spon-
taneous seal of an endoleak with demonstrated con-
sistent reduction in maximum transverse diameter
was classified as a success. Other outcome measures
were length of hospital stay, length of intensive care
unit stay, and operative blood loss.
OR group. Elective conventional OR operations
were performed in 195 patients. A total of 151 men
and 44 women with a mean age of 69 years were
studied. Patient characteristics of the group are sum-
marized in Table II. The OR group included
patients who had an American Society of Anes-
thetists classification of III and whose AAA morpho-
logic features were unsuitable for ER. No patients
with severe respiratory disease Boushy Category
III13 were in the OR group.
Technique of open aneurysm repair. Conven-
tional technique of open AAA repair with a midline
transperitoneal approach with the patient under
general anesthesia was used. Other measures includ-
ed routine use of prophylactic antibiotics, systemic
heparin anticoagulation (5000 U intravenously) at
the time of cross-clamping, and postoperative venti-
lation and monitoring in the intensive care unit.
Tube graft replacement of the infrarenal aorta was
used in 180 patients, and a bifurcated graft was used
in the remaining 15 because of associated aneurysm
disease in the iliac arteries. This ratio of tube to
bifurcated grafts reflects departmental policy of
using tube grafts whenever possible and in the pres-
ence of iliac artery ectasia. Albumin-coated knitted
Dacron grafts (C.R. Bard Inc. Haverhill, Mass.) (n =
161) and collagen-impregnated Hemashield knitted
Dacron grafts (Meadox Medical Boston Scientific)
(n = 34) were used for OR.
Follow-up. Follow-up was conducted by inter-
view, examination, and telephone. The New South
Wales Department of Births, Deaths, and Marriages
confirmed the date and cause of death in nine
patients who had not previously been able to be
traced.
RESULTS
ER group. ER was achieved in 95 of 108
patients (88%). Conversion to OR was required in
the remaining 13 patients. Eight (20%) of these con-
versions occurred in 41 operations in the first 2-year
period of the study, and five (8%) occurred in 67 in
the second 2-year period. The causes of failure have
been described in detail previously14 and are listed in
Table III. Secondary conversion to OR on a subse-
quent occasion was required in seven patients. The
causes for these secondary conversions were persis-
tent perianostomotic endoleak12 in five patients and
inadvertent covering of the renal arteries with the
endograft in two. Unlike the primary conversions,
these secondary conversions were distributed equal-
ly between the first and second halves of the study
period. The maximum transverse diameter decreased
in all but three patients in whom the AAA was
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Table II. Characteristics of patients who under-
went endoluminal and open repair AAA
Endoluminal Open
Mean age (yr) 70 69
Sex (M/F) 100/8 151/44
Diameter AAA (mean in cm) 5.3 5.6
Ischemic heart disease (%) 58 (63) 88 (45)
Hypertension (%) 37 (34) 58 (30)
Diabetes mellitis (%) 10 (9) 14 (7)
Renal impairment (%) 8 (7) 6 (3)
M, Male; F, female.
excluded. In two of these three patients the diame-
ter increase did not persist beyond 6 months. The
third patient remains under observation. Detailed
measurements of the maximum transverse diameter
have been reported previously.15 Successful repair in
the ER group included three patients with sponta-
neous seal of an endoleak and demonstrated reduc-
tion in maximum transverse diameter in follow-up.
Spontaneous seal in three of 13 patients with
endoleaks represented a rate of 23%.
Six perioperative deaths occurred, three of which
occurred in the 95 patients who underwent successful
ER. The remaining three occurred in patients who
required conversion from ER to OR. The cause of the
deaths was myocardial infarction (n = 3), renal failure
(n = 2), and multisystem failure (n = 1). The last men-
tioned death occurred in a patient with an ejection
function of 20% who had a right iliac artery thrombo-
sis, acute lower limb ischemia, renal failure, pulmonary
edema, and cardiac arrest. Late deaths occurred in 10
patients as a result of myocardial infarction (n = 6), liver
failure (n = 2), ruptured esophagus (n = 1), and bacte-
rial endocarditis/septicemia (n = 1). Local/vascular
complications and remote/systemic complications are
listed in Tables IV and V. No difference in morbidity or
mortality rate was noted between patients with femoral
artery access and those with iliac artery access.
Late endoleaks. Late endoleaks occurred in six
patients. These were the result of deflation of a
detachable balloon (one at 6 months), migration of
a distal attachment device (one at 11/2 years), com-
ponent separation in a modular prosthesis (one at 2
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Table III. Causes of failure leading to open repair
No.
Access problems 2
Balloon-related
Malfunction 1
Aortic rupture 1
Stent-related
Dislodgment 3
Graft thrombosis 1
Inability to deploy bifurcated graft 5
Total 13
Fig. 1. Kaplan-Meier curves for survival. No significant difference when analyzed by log-rank
test (p = 0.141).
Table IV. Local/vascular complications of endolu-
minal repair of AAA
No. %
Femoral artery damage 4 4
Perforation of iliac artery 2 2
Dissection of iliac artery 2 2
Graft stenosis 2 2
Common iliac artery occlusion 4 4
Endoleak
Perioperative 7 7
Late 6 6
Renal arteries covered 2 2
Bleeding 2 2
Wound complications 4 4
Total 28 26
years, one at 3 years), and short distal neck (one at 6
months, one at 3 years).
OR group. Eleven perioperative deaths
occurred in 195 patients who underwent OR. Eight
were caused by myocardial infarction, one by
arrhythmia and cardiac arrest, and two by renal fail-
ure. Ten late deaths occurred in the OR group.
Seven were caused by myocardial infarction, one by
arrhythmia and congestive cardiac failure, and two
by carcinoma of the lung. One failure at 9 months
was caused by aortoenteric fistula with gastrointesti-
nal bleeding. Local/vascular and remote/systemic
complications are listed in Table VI.
Comparison of outcome
Mortality and survival data. The perioperative
mortality rate was the same for both groups (5.6%).
No significant difference in survival rate was found
between the ER and OR groups when analyzed by
the log-rank test (p = 0.14). The Kaplan-Meier sur-
vival curves are shown in Fig. 1. The overall median
follow-up time was 34 months, with a median fol-
low-up of 29 months in the endoluminal group and
37 months in the open surgery group. No patients
were lost to follow-up.
Graft failure. The incidence of graft failure was
significantly higher in the endoluminal group (25 of
108) compared with the open group (1 of 195;
Fisher’s exact test, p < 0.001; Table VII). The causes
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Table V. Remote/systemic complications of endo-
luminal repair of AAA
No. %
Renal insufficiency
Renal artery ostia obstructed 2 2
Contrast media-induced 5 5
Cardiac
Congestive failure 2 2
Myocardial infarction 4 4
Cardiac arrhythmia 2 2
Stroke/TIA 3 3
Total 18 17
TIA, Transient ischemic attack.
Fig. 2. Kaplan-Meier curve for graft failure times for endoluminal group.
Table VI. Complications of open repair of AAA
No. Percent
Local/vascular
Abdominal wound dehiscence 7 4
Bowel obstruction 2 1
Common iliac artery occlusion 1 0.5
Peripheral embolization 3 2
Wound infection 4 2
17 9
Remote/systemic
Renal
Acute renal failure 9 5
Renal artery stenosis 1 0.5
Cardiac
Congestive failure 8 4
Myocardial infarction 11 6
Cardiac arrhythmia 7 4
Stroke/TIA 2 1
38 20
TIA, Transient ischemic attack.
of graft failure in 25 patients in the endoluminal
group comprised 13 that resulted in primary con-
version (Table III), seven that resulted in secondary
conversion (detailed in Results), and five endoleaks
that did not undergo conversion. Although three of
the last mentioned five patients have undergone suc-
cessful secondary ER, they have been classified as
failures in this study, which is limited to primary suc-
cess and not assisted success. The Kaplan-Meier
curve for graft failure times for the endoluminal
group revealed a 3-year graft success probability of
71%, with a 95% confidence interval (58%, 81%). A
log {– log(.)} transformation16 was used to calculate
the confidence interval (Fig. 2). Successful repair of
AAA in this group was defined as continuing graft
function without endoleak or conversion to OR. No
difference was found in predicting graft failure for
any of the devices except the modified Parodi, in
which 60% failed. As the first device used, this is
more a reflection of operator inexperience than
device failure. All deaths without previous graft fail-
ure have been considered as censored observations,
that is, credit has been given for successful repair up
to the time of death, but graft failure has not yet
occurred. Because only one failure occurred in the
open group, the log-rank test comparing graft fail-
ure times between the two treatment groups would
not be meaningful.
Length of hospital stay. The distribution of
number of days in the hospital after surgery was
skewed, with heavy ties for hospital discharge on
days 6 through 14. The length of hospital stay in
periods of 7 days was significantly shorter in the
endoluminal group compared with the open group
(Fisher’s exact test, p < 0.001; Table VIII). Because
the length of stay for all 303 patients was highly
skewed (minimum, 1 day; maximum, 77 days; aver-
age, 11.2 days), grouping the times into weekly
intervals enabled a more sensible interpretation of
the results to be deduced.
Duration of intensive care unit admission.
Admission to the intensive care unit was required in
43 of 108 patients after ER compared with 195 of
195 patients after OR. The duration of intensive
care unit admission in periods of 1 day was signifi-
cantly less in the endoluminal group (median 0)
compared with the open group (median, 1; Fisher’s
exact test, p < 0.001; Table IX). It must be remem-
bered, however, that it was departmental policy for
patients in the open group to routinely go to the
intensive care unit. None of the patients who under-
went successful ER required mechanical ventilation.
Blood loss at operation. Blood loss was signifi-
cantly less in the endoluminal group compared with
the open group (Fisher’s exact test, p < 0.001). The
quantities of blood loss in each group are detailed in
Table X. The figures refer to blood shed at operation
and not blood replacement, thus avoiding bias
caused by use of the cell saver in some patients.
DISCUSSION
This is the first study that has attempted to com-
pare the outcome of endoluminal treatment of AAA
with that of a concurrent control group that under-
went OR in consecutive patients. It must be
acknowledged at the outset, however, that the two
groups, although comparable in relation to age, sex,
and size of aneurysms, differed markedly with regard
to comorbidities. These were sufficiently severe in
44% of the endoluminal group to lead to rejection
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Table VII. Graft failure
Endoluminal         Open Total
Successful repair 83 194 277
Failed repair 25 1 26
Total 108 195 303
Fisher’s exact test, p < 0.001.
Table VIII. Length of hospital stay
Endoluminal Open Total
<1 week 44 32 76
1 to 2 weeks 49 133 182
2 to 3 weeks 10 17 27
>3 weeks 5 13 18
Total 108 195 303
Median (days) 8 9
Mean (days) 10.5 11.7
Fisher’s exact test, p < 0.001.
Table IX. Duration of intensive care unit admis-
sion
Endoluminal         Open Total
Nil 65 0 65
1 day 31 130 161
2 days 3 31 34
>3 days 9 34 43
Total 108 195 303
Median (days) 0 1
Mean (days) 0.8 2.1
Fisher’s exact test, p < 0.001.
for OR at major vascular centers. Despite this factor,
the perioperative mortality rate was identical for
both groups. It should also be pointed out that the
mortality rate for the endoluminal group includes
not only those who died after successful ER but also
those who died as a result of conversion from failed
ER to OR. Similarly, no significant difference was
found in survival rate between the two groups. One
interpretation of these results is that the two groups
are equally healthy. It seems more likely, however,
that members of the less-healthy endoluminal group
underwent a procedure of lesser magnitude, which
resulted in the same outcome as the healthier open
group who underwent a major open procedure.
There is general acceptance that the gold stan-
dard for comparing two methods of treatment is a
concurrent randomized study. When there is such a
vast difference, however, between the two methods
and the level of discomfort experienced by patients
in each group, it has become apparent that a ran-
domized trial is impractical. There is virtually no way
of preventing patients from withdrawing from a ran-
domized study if they fail to draw the minimally
invasive method, which many seek. If the trial hap-
pens to be a multicenter one, there are similar prob-
lems with preventing patients from registering with
several centers in a sequential manner until they
draw the method of their choice.
The limitations of this study must also be
addressed. The retrospective analysis of the data for
the open group may have underestimated the
instance of complications for this group. Regular fol-
low-up and use of contrast-enhanced computed
tomography in the endoluminal group make it high-
ly unlikely that any failures or complications would
be overlooked. The open group was not subjected
to such scrutiny. Only one failure from aortoenteric
fistula was encountered. It is possible that false
aneurysms may have been overlooked. The chance
of undetected failure from this cause, however, is
probably small because the incidence of false
aneurysm is low in the first 5 years after open AAA
repair.
Although the open and endoluminal operations
were performed by the same group of surgeons, the
endoluminal group carried the burden of the learn-
ing curve for a new technique. This is well illustrat-
ed in the fall in the primary conversion rate from
20% in the first half of the study to 8% in the second
half. The authors, however, deliberately included all
patients who underwent elective ER from the outset
of the program in May 1992, because they wished to
present a “worst case scenario” for ER to avoid any
unrealistic expectations for the procedure. For the
same reason, the life table curve for ER includes the
outcome for primary repair only. The improved
results that can be achieved with successful sec-
ondary ER, thus avoiding conversion to OR, have
been excluded.
The significance of endoleaks deserves further
comment. In the authors’ experience primary
endoleaks usually result from errors of judgment in
case selection or errors of technique. Secondary
endoleaks, however, usually result from endoluminal
device failure. In this regard it is reassuring to see
that the failure rate caused by device failure is limit-
ed to one per year in a group of 95 successful ERs in
108 patients.
It is concluded that ER is safe, sharing the same
mortality rate as OR despite almost half the ER group
being at high risk and unfit for OR. If successful repair
of AAA was the only criterion, the inescapable con-
clusion would be that OR is the most reliable method
of successfully managing AAA. Patients opting for the
endoluminal method of repair should be made aware
that the minimally invasive technique carries the dis-
advantage of a higher failure rate. Other factors, how-
ever, must be taken into account in assessing the rela-
tive merits of the two methods of aneurysm repair.
This study shows that the endoluminal method may
result in a shorter length of hospital stay, a shorter
length of intensive care unit stay, and less blood loss
than the open method. Despite these advantages it
must be emphasized that the endoluminal method is
not free of major morbidity and mortality.
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Dr. Edmund J. Harris, Jr. (Stanford, Calif.). Dr.
Abbott, Dr. Towne, members and guests. Professor May
and his group from Sydney return to us today with this
interesting update of their well-developed aortic aneurysm
endoluminal treatment program. As you recall, it was 2
years ago at the Forty-ninth Annual Meeting of this Soci-
ety that this group presented data for their initial 2-year
experience with the endoluminal repair of aneurysms and
compared these results with a historic control cohort of
patients who underwent standard open repair. Although
at that time the endoluminal group did not include all
consecutive patients treated with the endoluminal tech-
nique, the data presented showed that early morbidity
rate, mortality rate, and length of hospital stay were simi-
lar for both groups of roughly comparable patients. The
Sydney group then proposed that a randomized study to
compare the endoluminal method against a standard open
repair should be undertaken.
Subsequently, as Professor May and others have rec-
ognized, a true randomized trial comparing these two
methods is impractical. Initial attempts at randomization
were often foiled by patient withdrawal from the protocol
after randomization to the open procedure, a finding sup-
ported in this study by patient choice being the indication
for endoluminal repair in 55% of the repairs. Therefore a
concurrent comparison of these two methods as presented
in this report is generally accepted as a valid method of
comparison.
A 4-year period from the onset of the University of
Sydney endoluminal treatment program is reviewed, dur-
ing which 303 consecutive abdominal aortic aneurysms
underwent elective repair. Conventional open repair
accounted for 195 patients, and endoluminal repair was
used in 108 patients. Both series were prospective consec-
utive patients. Patients in whom endoluminal therapy was
attempted but was unsuccessful are included in the analy-
sis of the endoluminal group, unlike this group’s previous
reports in New Orleans. The actuarial survival rate was
similar between the two groups, but the 3-year graft fail-
ure rate was significantly higher in the endoluminal group.
Several other interesting observations were made that
lead me to ask several questions. Bifurcated grafts were
infrequent in the operative group, accounting for only 8%
of the total, whereas bifurcated stent-grafts were used in
the endoluminal repair group in 33% and aortoiliac with a
femorofemoral bypass grafting in another 23% of the
patients. Was there a difference in the aneurysm morpho-
logic features between the two treatment groups, or were
there technical or device constraints that led to this differ-
ence?
Hospital stays of fewer than 7 days were more com-
mon in the endoluminal repair group, yet hospital stays
longer than 2 weeks were similar between the two groups
at 14%. The article states that 45% of the patients in the
endoluminal repair group had comorbidities sufficiently
severe to preclude open repair at other medical centers.
Would these patients not be candidates for open repair at
the University of Sydney? The perioperative morbidity and
mortality rates were not significantly different between
these two groups, although the authors state that the
endoluminal repair group was at higher risk than the open
repair group.
Last year I presented a poster at the joint meeting that
presented our experience with 73 consecutive high-risk
patients who underwent open aneurysmorrhaphy with no
operative mortality. Clearly, the level of support in the
perioperative period has improved with time, and many
more patients perceived as being at high risk for open
aneurysm repair now may be offered a safe and durable
repair. What specific risk factors do the authors believe
preclude open aneurysm repair? If these constraints are
met by a patient, do the authors feel justified in offering
an endoluminal repair with the small but real possibility
that this procedure must be converted to an open
aneurysm repair?
The authors suggest in the article that the higher graft
failure rate in the endoluminal repair group was based on
poor judgment, yet two thirds of the late endoleaks appear
related to delayed device failure. I agree with the authors’
conclusions that open repair remains the most reliable
method of treating abdominal aortic aneurysms. I applaud
Professor May for critically reporting his extensive experi-
ence with endoluminal repair of aortic aneurysms, and I
look forward to future reports of his continuing work in
this exciting new field.
Dr. James May (Sydney, Australia). Thank you very
much, Edmund. In answer to your first question about the
configuration of the grafts, this was based on the mor-
phology of the aneurysms, which was similar in both
groups, rather than availability of endografts.
As far as the comorbidities were concerned, the
patients would have been excluded for open repair on our
terms and on those of vascular surgeons who felt they
were unfit.
As far as the justification for offering endoluminal
repair to fit patients with small aneurysms, I think that this
is premature at this stage to do that, but I can foresee that
when we have a little bit more follow-up, rather than
being confined to 4 or 5 years, that it will in fact be justi-
fiable to offer this to patients and hopefully using a simple
technique with a tube graft.
And finally, the cause for conversion, as I mentioned
this morning, the primary conversions usually result from
errors in patient selection or errors in technique. And in
our experience most of the secondary conversions have
resulted from device failure.
Dr. David C. Brewster (Boston, Mass.). I think all vas-
cular surgeons would certainly agree that the initial enthu-
siasm for endovascular aneurysm repair certainly needs to
be justified by long-term data. And Dr. May and his group
are to be congratulated for examining their very significant
experience in this regard.
I did want to ask for clarification about your definition
of endograft failure and particularly the influence or
impact of endoleak on classification of failure. I think
experience has shown that half of endoleaks will seal spon-
taneously and that a good number, if not most, endoleaks
can subsequently be managed by minimally invasive
endovascular techniques. So I just ask you, is it perhaps
too stringent to consider an endograft repair as a failed
procedure if any endoleak is present at any time, especial-
ly if such an endoleak either seals spontaneously or can be
corrected by subsequent minimally invasive methods? Cer-
tainly we all accept the concept of primary assisted paten-
cy of infrainguinal grafts, for example, that under surveil-
lance require minimal modification. Are you perhaps
being too stringent in terms of endoleak?
Dr. May. I don’t believe so. I think that endoluminal
repair is a new procedure, and it has to stand on its own
feet against the previous and established method of treat-
ment of open repair. And for that reason I have deliber-
ately included every patient that we have done from the
outset with primitive devices and so forth in the earlier
days. And I have also chosen not to put into those Kaplan-
Meier curves the improved results that can be obtained
from secondary endoluminal repair, so it is essentially a
worst case scenario that we have attempted to present.
Dr. Linda M. Reilly (San Francisco, Calif.). I would
like to ask the authors if they could comment on the fact
that the data they presented this morning in the breakfast
session indicate that their current results are substantially
better in terms of graft failure than the overall results pre-
sented in this article. By presenting your 4-year data in
summary like this, it could be misinterpreted that the rate
of initial failures is the same as current failure rates. And as
you mentioned this morning, and also Dr. Moore men-
tioned in the EVT trial, the rate of leaks is less with cur-
rent devices, the rate of conversion is less with current
devices. In our slowly accumulating series at UCSF, we
have performed approximately 35 endovascular aneurysm
repairs under protocol in the last 8 or 9 months, and we
have no conversions to open repair, and all four leaks were
treated successfully by endoluminal approaches. While it is
important to maintain a perspective on the appropriate use
of this technique for the treatment of standard aneurysms,
I think it is also important to recognize that the results are
considerably improved now compared with early results,
and it might be appropriate to separate your data into spe-
cific time intervals when you submit the article.
Dr. May. Yes, I agree with those comments. There is no
doubt that the results being achieved now with smaller
French size devices and with experience are far better than
were obtained in the first 21/2 years of this study. But I
think that is always going to be the case. If you start now
and you report in another 5 years time, the devices are
going to be better at the end of that time. And I think we
have got to be careful not to try and make too good a case
by subdividing your information in such a way that you
exclude the poorer results. But thank you very much for
the comment.
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